QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer

OBJECTIVE: A previous randomized phase II study showed that neoadjuvant nab-paclitaxel (nab-PTX) 100 mg/m(2)) was effective and well-tolerated in patients with HER2-negative early-stage breast cancer, compared with docetaxel (DTX). We evaluated patient outcomes in terms of the Functional Assessment...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Eur J Breast Health
Prif Awduron: Okuyama, Hiromi, Nakamura, Seigo, Akashi-Tanaka, Sadako, Sawada, Terumasa, Kuwayama, Takashi, Handa, Satoko, Kato, Yasuhisa
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Turkish Federation of Breast Diseases Associations 2018
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6170019/
https://ncbi.nlm.nih.gov/pubmed/30288492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/ejbh.2018.4174
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg